N2 Jenomics Lab Pvt. Ltd. offers SNP genotyping using the simple and affordable SNaPshot Multiplex System to allow efficient and quick results.
The SNaPshot Multiplex System is a sophisticated SNP genotyping technology developed by Applied Biosystems (ABI). Often referred to as "mini-sequencing," this method is based on fluorescently labeled single-base extension principles. It excels in genotyping multiple single nucleotide polymorphisms (SNPs) simultaneously within a single reaction. SNaPshot's core technology involves using fluorescently tagged dideoxynucleotides (ddNTPs) to terminate the extension of DNA primers after the addition of one nucleotide, allowing for precise determination of SNPs based on the emitted fluorescence.

Figure 1. SNaPshot assay principle schematic.
The SNaPshot assay operates through a methodical and efficient workflow that encompasses several crucial steps:
This approach facilitates the simultaneous analysis of up to 16 SNPs in a single reaction, making it highly efficient for medium-throughput genotyping projects.
N2 Jenomics Lab Pvt. Ltd. offers extensive SNaPshot genotyping services tailored to meet diverse research requirements. Leveraging cutting-edge SNaPshot technology, N2 Jenomics Lab Pvt. Ltd. ensures high-throughput SNP genotyping with unmatched accuracy and efficiency. Our service suite includes:
Our SNaPshot genotyping service supports projects involving the analysis of 8 to 16 SNPs across several hundred to thousands of samples, making it particularly suitable for large-scale genetic studies and applications.
SNaPshot genotyping offers several distinct advantages:
SNaPshot genotyping technology finds application in diverse research and clinical contexts, including:
The versatility and precision of SNaPshot make it an invaluable tool in both academic research and applied genetic studies, offering robust capabilities for a multitude of genetic investigations.
Firstly, the primers are used to amplify the target SNPs fragment, and Exo I and the Shrimp Alkaline Phosphatase (SAP) are added to the amplification products to digest the primer and the remaining dNTPs. Then, the purified products are used as templates, and the PCR is performed using the sequencing enzyme, four fluorescent labeling ddNTP and the 5'- terminal extension primers close to the SNP site. The primers extend one base only. After the ABI sequencer, the corresponding SNP loci are determined according to the position and color of the peak. According to the color of the peak, we can know the type of the base, and identify the gene sequence of the sample. It is usually used for analysis of 3 to 30 SNP sites. A typical SNaPshot Multiplex System for SNP genotyping workflow is shown as follow:

Sample Requirements
Note: Sample amounts are listed for reference only. For detailed information, please contact us with your customized requests. | |
![]()
| Sequencing Strategy
|
Bioinformatics Analysis
Note: Recommended data outputs and analysis contents displayed are for reference only. For detailed information, please contact us with your customized requests. |

Partial results are shown below:

1. Can SNaPshot detect sample contamination?
Yes, the SNaPshot assay can identify the presence of exogenous DNA contamination by analyzing the height ratios of the dual peaks in the electropherogram. This method provides a reliable means to assess sample integrity.
2. Can the SNaPshot method detect unknown polymorphisms?
Yes, the SNaPshot method is capable of detecting unknown polymorphisms, provided that the sequences flanking the mutation site are known. This allows for accurate base identification at the target site.
3. Can SNaPshot Be Used for Whole-Genome SNP Analysis?
The SNaPshot assay is tailored for targeted SNP genotyping, making it highly effective for analyzing specific SNPs rather than performing a comprehensive whole-genome SNP analysis. For extensive genomic studies that require a broad examination of SNPs across the entire genome, other technologies such as SNP arrays or next-generation sequencing (NGS) offer greater coverage and throughput.
TIMD4 rs6882076 SNP Is Associated with Decreased Levels of Triglycerides and the Risk of Coronary Heart Disease and Ischemic Stroke
Journal: International Journal of Medical Sciences
Impact factor: 3.2
Published: 2019 Jun 2
Background
Coronary heart disease (CHD) and ischemic stroke (IS) are major health concerns linked to atherosclerosis and shared risk factors. This study examined the TIMD4 rs6882076 SNP using Snapshot Technology in 1,765 individuals (581 with CHD, 559 with IS, and 625 controls) to explore its association with CHD, IS, and serum lipid levels.
Materials & Methods
Sample Preparation:
Method:
Data Analysis:
Results
The study compared clinical and genetic characteristics between patients with CHD or IS and healthy controls. It found that patients with CHD or IS had higher body weight, BMI, systolic blood pressure, triglycerides (TG), and hypertension rates, but lower total cholesterol (TC), HDL-C, ApoA1, and ApoA1/ApoB ratio compared to controls. The TIMD4 rs6882076 SNP showed different genotypic and allelic frequencies between patients and controls. T allele carriers had a reduced risk of both CHD and IS. In controls, T allele carriers had lower TG levels compared to non-carriers, though this was not significant in patients with CHD or IS. Multivariate analysis identified alcohol consumption, high BMI, and hyperlipidemia as risk factors for both CHD and IS, while smoking was a risk factor for CHD but not IS.
Table 2 Genotypic and Allelic Frequencies of the TIMD4 rs6882076 SNP and the Risk of CHD and IS [n (%)]

Table 3 The TIMD4 rs6882076 SNP and the Risk of CHD and IS According to Gender, Age, Body Mass Index, Smoking Status and Alcohol Consumption

Conclusion
The TIMD4 rs6882076 SNP is linked to lower serum triglyceride (TG) levels and reduced risk of coronary heart disease (CHD) and ischemic stroke (IS) in the Southern Chinese Han population. T allele carriers have a decreased risk of both conditions and lower TG levels compared to non-carriers. This suggests that the SNP may lower CHD and IS risk by reducing serum TG levels.
Reference:


